Cornelius J Clancy1, Peter G Pappas2, Jose Vazquez3, Marc A Judson4, Dimitrios P Kontoyiannis5, George R Thompson6, Kevin W Garey7, Annette Reboli8, Richard N Greenberg9, Senu Apewokin10, G Marshall Lyon11, Luis Ostrosky-Zeichner12, Alan H B Wu13, Ellis Tobin14, M Hong Nguyen1, Angela M Caliendo15. 1. University of Pittsburgh Medical Center, Pennsylvania. 2. University of Alabama at Birmingham Hospital, New York. 3. Medical College of Georgia, Augusta University, New York. 4. Albany Medical College, New York. 5. M.D. Anderson Cancer Center, Houston, Texas. 6. University California Davis Medical Center, Sacramento. 7. University of Houston College of Pharmacy, Texas. 8. Cooper Medical School of Rowan University and Cooper University Healthcare, Camden, New Jersey. 9. University of Kentucky Medical Center, Lexington. 10. University of Arkansas Medical System, Little Rock. 11. Emory Healthcare, Atlanta, Georgia. 12. University of Texas Health Science Center, Houston. 13. University of California, San Francisco. 14. St. Peters Healthcare System, Albany, New York. 15. Alpert Medical School of Brown University, Providence, Rhode Island.
Abstract
Background: Blood cultures are approximately 50% sensitive for diagnosing invasive candidiasis. The T2Candida nanodiagnostic panel uses T2 magnetic resonance and a dedicated instrument to detect Candida directly within whole blood samples. Methods: Patients with Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, or Candida krusei candidemia were identified at 14 centers using diagnostic blood cultures (dBCs). Follow-up blood samples were collected concurrently for testing by T2Candida and companion cultures (cBCs). T2Candida results are reported qualitatively for C. albicans/C. tropicalis, C. glabrata/C. krusei, and C. parapsilosis. T2Candida and cBCs were positive if they detected a species present in the dBC. Results: Median time between collection of dBC and T2Candida/cBC samples in 152 patients was 55.5 hours (range, 16.4-148.4). T2Candida and cBCs were positive in 45% (69/152) and 24% (36/152) of patients, respectively (P < .0001). T2Candida clinical sensitivity was 89%, as positive results were obtained in 32/36 patients with positive cBCs. Combined test results were both positive (T2+/cBC+), 21% (32/152); T2+/cBC-, 24% (37/152); T2-/cBC+, 3% (4/152); and T2-/cBC-, 52% (79/152). Prior antifungal therapy, neutropenia, and C. albicans candidemia were independently associated with T2Candida positivity and T2+/cBC- results (P values < .05). Conclusions: T2Candida was sensitive for diagnosing candidemia at the time of positive blood cultures. In patients receiving antifungal therapy, T2Candida identified bloodstream infections that were missed by cBCs. T2Candida may improve care by shortening times to Candida detection and species identification compared to blood cultures, retaining sensitivity during antifungal therapy and rendering active candidemia unlikely if results are negative. Clinical Trials Registration: NCT01525095.
Background: Blood cultures are approximately 50% sensitive for diagnosing invasive candidiasis. The T2Candida nanodiagnostic panel uses T2 magnetic resonance and a dedicated instrument to detect Candida directly within whole blood samples. Methods:Patients with Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, or Candida krusei candidemia were identified at 14 centers using diagnostic blood cultures (dBCs). Follow-up blood samples were collected concurrently for testing by T2Candida and companion cultures (cBCs). T2Candida results are reported qualitatively for C. albicans/C. tropicalis, C. glabrata/C. krusei, and C. parapsilosis. T2Candida and cBCs were positive if they detected a species present in the dBC. Results: Median time between collection of dBC and T2Candida/cBC samples in 152 patients was 55.5 hours (range, 16.4-148.4). T2Candida and cBCs were positive in 45% (69/152) and 24% (36/152) of patients, respectively (P < .0001). T2Candida clinical sensitivity was 89%, as positive results were obtained in 32/36 patients with positive cBCs. Combined test results were both positive (T2+/cBC+), 21% (32/152); T2+/cBC-, 24% (37/152); T2-/cBC+, 3% (4/152); and T2-/cBC-, 52% (79/152). Prior antifungal therapy, neutropenia, and C. albicans candidemia were independently associated with T2Candida positivity and T2+/cBC- results (P values < .05). Conclusions: T2Candida was sensitive for diagnosing candidemia at the time of positive blood cultures. In patients receiving antifungal therapy, T2Candida identified bloodstream infections that were missed by cBCs. T2Candida may improve care by shortening times to Candida detection and species identification compared to blood cultures, retaining sensitivity during antifungal therapy and rendering active candidemia unlikely if results are negative. Clinical Trials Registration: NCT01525095.
Authors: John P Bomkamp; Rand Sulaiman; Jennifer L Hartwell; Armisha Desai; Vera C Winn; Justin Wrin; Michelle L Kussin; Jon J Hiles Journal: J Clin Microbiol Date: 2020-02-24 Impact factor: 5.948
Authors: Marie von Lilienfeld-Toal; Johannes Wagener; Hermann Einsele; Oliver A Cornely; Oliver Kurzai Journal: Dtsch Arztebl Int Date: 2019-04-19 Impact factor: 5.594
Authors: Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart Journal: J Clin Microbiol Date: 2021-06-18 Impact factor: 5.948